SGLT2 Inhibitors in ADPKD: Mechanistic Insights and Therapeutic Promise.

ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes. Tolvaptan remains the only FDA-approved disease-modifying therapy, yet its tolerability and safety profile highlight the need for additional strategies. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for glycemic control, have demonstrated robust kidney- and cardio- protective effects across diverse patient populations, including those without diabetes. By lowering intraglomerular pressure, metabolic reprogramming, and attenuating hypoxic microenvironment and inflammation, SGLT2i target mechanisms that are relevant to ADPKD. However, concerns that SGLT2i may provoke osmotic diuresis and activate vasopressin led to systematic exclusion of patients with ADPKD from pivotal outcome trials. The 2025 KDIGO ADPKD guidelines explicitly advise against the use of SGLT2i for slowing kidney function decline in ADPKD. In this review, we examine mechanistic intersections between SGLT2i and ADPKD pathophysiology, summarize available preclinical and early clinical data, and discuss ongoing large trials designed to address safety and efficacy of SGLT2i in patients with ADPKD. We also highlight the importance of genetic heterogeneity, as most ongoing trials are enriched for rapid progressors carrying PKD1 or PKD2 pathogenic variants, while other genotypes such as DNAJB11, ALG8, and ALG9, often associated with greater interstitial fibrosis, are underrepresented. Substratification of patients by genotype, risk of progression, and comorbidities will be essential to guide precision application of SGLT2i. Whether SGLT2i can ultimately be positioned as an adjunctive or standalone therapy for ADPKD remains unresolved.

• Publication year

  2025

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.0000000943PMID 41212622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erratum to "Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan" [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075].

  2025cited by this paper
• Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series

  2025cited by this paper
• SGLT2 inhibition for patients with ADPKD – closing the evidence gap

  2025cited by this paper
• SGLT2i delays c-Myc-induced HCC progression via targeting mTOR.

  2025cited by this paper
• Acute hypoxia modulate macrophage phenotype accompanied with transcriptome re-programming and metabolic re-modeling

  2025cited by this paper
• KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

  2025cited by this paper
• KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.

  2025cited by this paper
• Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan

  2025cited by this paper
• Gut microbiota and kidney function in autosomal dominant polycystic kidney disease participants in Cameroon: a cross-sectional study

  2025cited by this paper
• Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats

  2024cited by this paper
• The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice

  2024cited by this paper
• Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial

  2024cited by this paper
• Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions

  2024cited by this paper
• Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease

  2024cited by this paper
• State-of-the-art-review Mechanisms of action of SGLT2 inhibitors and clinical implications.

  2024cited by this paper
• Kidney Measurement and Glomerular Filtration Rate Evolution in Children with Polycystic Kidney Disease

  2024cited by this paper
• Cellular and Mitochondrial Pathways Contribute to SGLT2 Inhibitors-mediated Tissue Protection: Experimental and Clinical Data.

  2024cited by this paper
• SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback

  2024cited by this paper
• Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment

  2024cited by this paper
• Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins

  2023cited by this paper
• Metabolic Communication by SGLT2 Inhibition

  2023cited by this paper
• Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD

  2023cited by this paper
• Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease

  2023cited by this paper
• Cardiovascular Involvement in Patients with Autosomal Dominant Polycystic Kidney Disease: A Review

  2023cited by this paper
• Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects

  2023cited by this paper
• Short-Term Dapagliflozin Administration in Autosomal Dominant Polycystic Kidney Disease—A Retrospective Single-Arm Case Series Study

  2023cited by this paper
• CFTR and PC2, partners in the primary cilia in ADPKD.

  2023cited by this paper
• Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control - from bedside to bench.

  2023cited by this paper
• SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

  2023cited by this paper
• SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence

  2023cited by this paper
• SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in non-diabetic rats.

  2022cited by this paper
• Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

  2022cited by this paper
• Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy.

  2022cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022cited by this paper
• SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial

  2022cited by this paper
• Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD

  2022cited by this paper
• Does autosomal dominant polycystic kidney disease increase the risk of aortic aneurysm or dissection: a point of view based on a systematic review and meta-analysis

  2022cited by this paper
• SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function

  2022cited by this paper
• Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis

  2022cited by this paper
• The Effect of ß-Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial

  2022cited by this paper
• Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cited by this paper
• Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.

  2022cited by this paper
• Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages.

  2022cited by this paper
• Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.

  2021cited by this paper
• Effects of SGLT2 Inhibitor and Dietary NaCl on Glomerular Hemodynamics Assessed by Micropuncture in Diabetic Rats.

  2021cited by this paper
• Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

  2021cited by this paper
• Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy

  2021cited by this paper
• Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review

  2021cited by this paper
• Echocardiographic Findings and Genotypes in Autosomal Dominant Polycystic Kidney Disease

  2021cited by this paper
• The Mechanism of CD8+ T Cells for Reducing Myofibroblasts Accumulation during Renal Fibrosis

  2021cited by this paper
• Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States

  2021cited by this paper
• Tubuloglomerular Feedback Synchronization in Nephrovascular Networks

  2021cited by this paper
• Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

  2021cited by this paper
• Cardiovascular Disease in Chronic Kidney Disease

  2021cited by this paper
• The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature

  2020cited by this paper
• Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?

  2020cited by this paper
• SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.

  2020cited by this paper
• The tubular hypothesis of nephron filtration and diabetic kidney disease

  2020cited by this paper
• Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney

  2020cited by this paper
• Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance

  2020cited by this paper
• Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

  2020cited by this paper
• Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

  2020cited by this paper
• Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume

  2020cited by this paper
• Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

  2020cited by this paper
• The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.

  2020cited by this paper
• Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma

  2020cited by this paper
• Excessive ROS Production and Enhanced Autophagy Contribute to Myocardial Injury Induced by Branched-chain Amino Acids: Roles for the AMPK-ULK1 Signaling Pathway and α7nAChR.

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020cited by this paper
• A role for the tubular Na+-H+-exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.

  2020cited by this paper
• Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials.

  2020cited by this paper
• The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

  2020cited by this paper
• Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha

  2020cited by this paper
• Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury

  2020cited by this paper
• Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging.

  2019cited by this paper
• SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.

  2019cited by this paper
• Macrophages: versatile players in renal inflammation and fibrosis

  2019cited by this paper
• SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

  2019cited by this paper
• Autosomal dominant polycystic kidney disease

  2019cited by this paper
• The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

  2019cited by this paper
• Knockout of Na-glucose-cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase-1 in macula densa and glomerular hyperfiltration

  2019cited by this paper
• Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

  2019cited by this paper
• ALG9 Mutation Carriers Develop Kidney and Liver Cysts.

  2019cited by this paper
• Metabolic reprogramming and the role of mitochondria in polycystic kidney disease.

  2019cited by this paper
• SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.

  2018cited by this paper
• Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

  2018cited by this paper
• A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.

  2018cited by this paper
• Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study

  2018cited by this paper
• A Large Database Analysis of Rates of Aneurysm Screening, Elective Treatment, and Subarachnoid Hemorrhage in Patients With Polycystic Kidney Disease.

  2018cited by this paper
• Canagliflozin exerts anti‐inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells

  2018cited by this paper
• Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis

  2018cited by this paper
• Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

  2018cited by this paper
• Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model.

  2018cited by this paper
• HIF-1α drives cyst growth in advanced stages of autosomal dominant polycystic kidney disease.

  2018cited by this paper
• MicroRNA501‐5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells

  2018cited by this paper
• Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

  2018cited by this paper
• CD8+ T cells modulate autosomal dominant polycystic kidney disease progression

  2018cited by this paper
• A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

  2018cited by this paper
• SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

  2018cited by this paper
• Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?

  2018cited by this paper
• Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis

  2017cited by this paper

• No citing papers are available for this paper.